You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
A federal court said Guardant CEO Helmy Eltoukhy deleted emails pertaining to two similar cases, but it remains unclear whether he did so intentionally.
St. Jude Children's Research Hospital researchers evaluated a microbial cell-free DNA sequencing test from infectious disease diagnostics firm Karius.
Effective Feb. 3, 2020, the donor-derived cell-free DNA test will be covered for all kidney transplant recipients, including those with multiple kidney transplants.
CareDx claims that Eurofins Viracor infringes on its patent related to noninvasive monitoring of organ transplant rejection through cell-free DNA analysis.
Cyclomics, a 2018 spinout from University Medical Center Utrecht, is testing its assay for treatment response and recurrence monitoring in head and neck cancer.
Researchers at Harvard, Peking University, and Yikon Genomics suggested that their noninvasive test is more specific than the prevailing biopsy-based method.
MSK-ACCESS sequences 129 cancer-associated genes selected from the MSK-IMPACT assay and is designed to detect gene alterations in cfDNA specimen.
Resolution is developing its liquid biopsy assay as a companion diagnostic for niraparib in metastatic castration-resistant prostate cancer.
SensID specializes in the development, manufacture, and marketing or reference materials and quality controls for DNA-based diagnostics.
The company's first quarter revenues were driven by sales of its noninvasive prenatal screening and carrier screening tests.